TriGemX Bio
PrivateLast Round
Early Funding
Oct 1, 2026
Est. Valuation
$1.27B
Total Funding Raised
$581.2M
Company Overview
TriGemX Bio is a biotechnology company focused on developing elismetrep, a first-in-class TRPM8 channel blocker for the treatment of migraine.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TriGemX Bio Comparables
Compare TriGemX Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nura Bio | 64% | |
| Latigo Biotherapeutics | 59% | |
| RaQualia Pharma, Inc. | 50% |
TriGemX Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Oct 1, 2026 | ||||
| Grant | May 10, 2023 | ||||
| Series D | Feb 15, 2022 | ||||
| Series C | Mar 25, 2020 | ||||
| Series B | Dec 5, 2018 | ||||
Series A | Dec 10, 2015 |
TriGemX Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | Series A, Series B, Series C, Early Funding, Series D |
| TCG Crossover | Early Funding |
| Greenspring Associates | Series C |
| Parkwood | Series D |
| StepStone Group | Series D |
| Lux Capital | Series A, Series B, Series D, Series C |
| Gates Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2026
Raised $94M Early Funding round
- May 10, 2023
Raised $8M Grant round
TriGemX Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about TriGemX Bio's valuation, stock price, and market status.
Is TriGemX Bio a public or private company?
TriGemX Bio is a private company.
What is the current stock price of TriGemX Bio?
TriGemX Bio is a private company with no public stock price. Caplight tracks TriGemX Bio's secondary market activity and provides MarketPrice™ estimates to Caplight users.
How much is TriGemX Bio worth (valuation)?
TriGemX Bio's valuation is estimated at $1.3B based on funding round data.
Can I buy TriGemX Bio stock?
TriGemX Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was TriGemX Bio's last funding round?
TriGemX Bio's most recent funding round was Early Funding on February 15, 2022.
Who are the main investors in TriGemX Bio?
Key investors in TriGemX Bio include The Column Group, TCG Crossover, Viking Global Investors, Mubadala Investment Company.
Will TriGemX Bio IPO soon?
No public IPO plans have been announced for TriGemX Bio.
How can I track TriGemX Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor TriGemX Bio's secondary market activity and sign up for updates.